Jasper Data Show Potential Promise For Anti-CD117 Conditioning Agent

 
• By Alaric DeArment

Jasper announced data on the first three patients in the trial of briquilimab in sickle cell disease and beta-thalassemia patients, not long after another player, Magenta, announced a setback in its program.

Jasper announced early data for briquilimab, its CD117-directed monoclonal antibody • Source: Shutterstock

More from Blood and Clotting

More from Therapy Areas